NCT01390571View on ClinicalTrials.gov

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

June 20, 2017

Study Completion Date

June 20, 2017

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

olaparib

DRUG

temozolomide

GENETIC

gene expression analysis

GENETIC

protein expression analysis

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

diffusion-weighted magnetic resonance imaging

PROCEDURE

dynamic contrast-enhanced magnetic resonance imaging

PROCEDURE

therapeutic conventional surgery

Trial Locations (7)

BS2 8ED

Bristol Haematology and Oncology Centre, Bristol

CB2 0QQ

Addenbrooke's Hospital, Cambridge

Unknown

Christie Hospital, Manchester

Royal Marsden Hospital, Sutton

Beatson West of Scotland Cancer Centre, Glasgow

B15 2TH

Queen Elizabeth Hospital, Birmingham

EH4 2XU

Western General Hospital, Edinburgh

Sponsors

Lead Sponsor

Cancer Research UK
All Listed Sponsors
lead

Cancer Research UK

OTHER

NCT01390571 - Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma | Biotech Hunter | Biotech Hunter